Marya Postner

Partner
Full contact info

Experience

Forbius Agrees to Sell to Bristol Myers Squibb

August 25, 2020

Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases – on its agreement to sell to Bristol Myers Squibb. Barbara Borden, Marya Postner and Rowook Park led the Cooley team advising Forbius. 

Read more

Related contacts

Rowook Park
Partner, San Diego
Barbara Borden
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
David Dalton
Associate, Los Angeles Santa Monica
Xander Lee
Partner, Los Angeles Santa Monica
Lindsey O'Crump
Associate, Washington DC
Marya Postner
Partner, Palo Alto
Michael Tuscan
Partner, Washington DC
Aaron Pomeroy
Partner, Colorado
Barbara Mirza
Partner, Los Angeles Santa Monica
Ross Eberly
Partner, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Jane Adams
Partner, San Diego
Jeffery Wyzykowski
Patent Agent, Washington DC
Phil Mitchell
Partner, New York
Steve Cuss
Associate, London
Tanya Heare-Rowlands
Special Counsel, London

Related Practices & Industries

October 15, 2020

Related contacts

Marya Postner
Partner, Palo Alto

Sangamo Announces Global Licensing Collaboration Agreement with Biogen

April 10, 2020

Cooley advised Sangamo Therapeutics, a clinical-stage biotechnology company, in its global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases.

Under the terms of the agreement, Sangamo will receive $225 million from the purchase by Biogen of newly issued Sangamo stock as well as an upfront license fee of $125 million. Additionally, Sangamo is eligible to earn up to $2.37 billion in other development, regulatory and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1.445 billion in first commercial sale and other sales-based milestone payments. Sangamo is also eligible to earn tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.

Related contacts

Marya Postner
Partner, Palo Alto
Jennifer Raab
Special Counsel, Palo Alto

Related Practices & Industries

Jazz Pharma Announces Exclusive License Agreement with PharmaMar

December 20, 2019

Cooley advised Jazz Pharmaceuticals, a specialty biopharmaceutical company focused on identifying, developing and commercializing products that address unmet medical needs, in its exclusive license agreement with PharmaMar for lurbinectedin in the United States. Under the terms of this agreement, PharmaMar will receive an upfront payment of $200 million with potential regulatory milestone payments of up to $250 million upon the achievement of accelerated and/or full regulatory approval of lurbinectedin by FDA within certain timelines. PharmaMar is also eligible to receive up to $550 million in potential commercial milestone payments, as well as incremental tiered royalties on future net sales of lurbinectedin ranging from the high teens up to 30 percent.

Related contacts

Marya Postner
Partner, Palo Alto
Jennifer Raab
Special Counsel, Palo Alto

Related Practices & Industries

Iconic Therapeutics Announces Option and License Agreement with Exelixis

May 17, 2019

Cooley advised Iconic Therapeutics, a private biopharmaceutical company focused on cancer and retinal disease, in its exclusive option and license agreement with Exelixis to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer. Under the terms of the agreement, Exelixis will gain an exclusive option to license ICON-2, Iconic’s lead oncology ADC program, in exchange for an upfront option payment to Iconic of $7.5 million and a commitment of preclinical development funding. Exelixis would exercise its option at the time of a potential IND application, and upon doing so would make an option exercise payment to Iconic and assume responsibilities for all subsequent clinical development and commercialization activities. Should Exelixis elect to exercise its option, Iconic will become eligible for future development, regulatory and commercialization milestone payments, as well as royalties on potential sales.

Related contacts

Marya Postner
Partner, Palo Alto

Related Practices & Industries

View more

Rankings & accolades

Chambers USA: Life Sciences: Corporate/Commercial – California (2020 – 2023)

Legal 500: Healthcare: Life Sciences “Key Lawyer”

LMG Life Sciences: Finance & Transactional “Star”

Best Lawyers in America: Biotechnology Law

IAM Patent 1000: Go-to for Biotech and Biopharmaceutical Companies

Who’s Who of Legal

Memberships & affiliations

American Bar Association

Sigma Xi

American Association for the Advancement of Science

Respected transactional practice counseling life sciences companies in a broad range of matters, including licensing, joint ventures and collaborations.

Chambers USA: Life Sciences: Corporate/Commercial – California (2022)

There is no one better at drafting in the industry.

Chambers USA: Life Sciences: Corporate/Commercial – California (2022)